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Introduction
Hematopoietic stem cells (HSCs) are rare cells endowed with 
multipotency and self-renewing ability that are capable of gen-
erating every specialized cell of the blood system.1 HSCs exist 
mainly in a quiescent state in vivo, while their immediate descen-
dants, the early hematopoietic progenitors, constitute a highly 
proliferative compartment.2,3 Precise regulation of HSC prolifera-
tion and cell fate decisions are necessary for production of mature 
blood cells throughout adult life, either under homeostasis or in 
instances that require rapid regenerative responses.4 Several posi-
tive and negative regulators of the cell cycle machinery are criti-
cal for various aspects of HSC and/or progenitor proliferation, 
including the cyclin-dependent kinase inhibitors p21,5-7 p27,8,9 
p57,9,10 p16,11 and p18,12 as well as the D-type cyclins13 and their 
catalytic partners Cdk4 and Cdk6.14
Cyclins associate with cyclin-dependent kinases (CDKs), 
thereby activating their kinase activity, which is key to the regu-
lation of biological processes, such as cell cycle progression and 
regulation of transcription.15,16 In mammals, the cyclin E sub-
family includes cyclins E1 and E2, which preferentially associate 
with—and activate—the catalytic subunit Cdk2.17-20 In physi-
ological conditions, cyclin E/Cdk2 complexes show periodic 
activation during the cell cycle, starting at the G
1
/S transition 
and persisting for the duration of the S phase.21 The genes encod-
ing cyclins E1 and E2 (Ccne1 and Ccne2) show similar and wide-
spread tissue distributions,22 and deletion of either gene alone 
revealed no obvious phenotype in mice.23,24 Combined knockout 
of Ccne1 and Ccne2 did not impair embryonic development per se, 
but caused lethality at mid-gestation owing to a placental defect, 
following from the failure of giant trophoblastic cells to undergo 
endo-replication.23,24 Characterization of double-knockout 
(dKO) mouse embryo fibroblasts (MEFs) confirmed that cyclins 
E1 and E2 are not essential for cell proliferation altogether, but 
unraveled their requirement for cell cycle re-entry upon growth 
factor stimulation of quiescent cells.23 Given the prominent role 
of quiescence and cell cycle re-entry in HSC biology, we decided 
to analyze the role of E-type cyclins in this particular cellular 
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A precise balance between quiescence and proliferation is crucial for the lifelong function of hematopoietic stem cells 
(HSCs). Cyclins e1 and e2 regulate exit from quiescence in fibroblasts, but their role in HSCs remains unknown. Here, we 
report a non-redundant role for cyclin e1 in mouse HSCs. A long-term culture-initiating cell (LtC-IC) assay indicated that 
the loss of cyclin e1, but not e2, compromised the colony-forming activity of primitive hematopoietic progenitors. Ccne1−/− 
mice showed normal hematopoiesis in vivo under homeostatic conditions but a severe impairment following myeloabla-
tive stress induced by 5-fluorouracil (5-FU). Under these conditions, Ccne1−/−HSCs were less efficient in entering the cell 
cycle, resulting in decreased hematopoiesis and reduced survival of mutant mice upon weekly 5-FU treatment. the role of 
cyclin e1 in homeostatic conditions became apparent in aged mice, where HSC quiescence was increased in Ccne1−/− ani-
mals. on the other hand, loss of cyclin e1 provided HSCs with a competitive advantage in bone marrow serial transplanta-
tion assays, suggesting that a partial impairment of cell cycle entry may exert a protective role by preventing premature 
depletion of the HSC compartment. our data support a role for cyclin e1 in controlling the exit from quiescence in HSCs. 
this activity, depending on the physiological context, can either jeopardize or protect the maintenance of hematopoiesis.
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compartment. Our results reveal an unexpected non-redundant 
requirement for cyclin E1 in HSCs.
Results
Cylin E1 deficiency affects early hematopoietic progenitors 
in vitro
Since regulation of the cell cycle is germane to the tight balance 
between differentiation and self-renewal, we decided to assess the 
function of cyclins E1 and E2 in murine HSCs and hematopoi-
etic progenitors. We first probed primitive hematopoietic cells 
in a long-term culture initiating cell (LTC-IC) assay. Bone mar-
row mononucleated cells (BMCs) were grown for 5 weeks on a 
feeder layer of stromal cells in order to allow proliferation and 
terminal differentiation of hematopoietic progenitors. The cells 
were then transferred onto a semisolid medium supplemented 
with a cocktail of cytokines promoting proliferation and differ-
entiation of primitive hematopoietic cells (in particular HSCs). 
Colonies formed in these secondary cultures arise from HSCs 
and hematopoietic progenitors that have withstood the initial 5 
weeks due to their low mitotic activity and their high self-renewal 
potential. Loss of cyclin E1 significantly reduced the number 
of colonies scored in the LTC-IC assay, while loss of cyclin E2 
had no effect (Fig. 1A). The few colonies scored in plates seeded 
with Ccne1−/− BMCs were also much smaller, a feature typical of 
primitive colonies composed of poorly differentiated hematopoi-
etic cells (Fig. 1B). This reduction in colony formation observed 
with Ccne1−/− cells correlated with a reduction in areas of hema-
topoiesis (cobblestone areas)25 observed at 5 weeks of culture on 
feeder layers (Fig. 1C). In contrast with the result of the LTC-IC 
assay, the frequency and proliferation of committed progenitors 
upon direct plating were unaffected by the loss of either cyclin 
E1 or E2, as measured by a colony-forming unit (CFU) assay 
(Fig. 1D; Fig. S1). Consistent with this result, FACS analysis 
showed that common lymphoid progenitors26 and myeloid pro-
genitors27 occurred at similar frequencies in the bone marrow of 
wild-type and Ccne1−/− animals (Fig. 1E; Fig. S2).
Altogether, our data pointed to a selective requirement for 
cyclin E1, but not cyclin E2, in cytokine-mediated prolifera-
tion of primitive hematopoietic progenitors. We thus focused 
our attention on possible hematopoietic defects in Ccne1−/− mice 
in vivo.
Figure 1. Analysis of progenitors and primitive hematopoietic cells derived from cyclin e mice of mixed background. (A) LtC-IC assay performed with 
250 000 BMCs isolated from 3 independent mice of the indicated genotypes. the graph reports the average number of colonies scored for the appropri-
ate genotypes, ± stdv. (B) Representative pictures of the colonies obtained in an LtC-IC assay using BMCs derived from Ccne1+/+ or Ccne1−/− mice. Scale bar 
is 400 µm. (C) CAFC assay; 2 independent experiments are shown performed on Ccne1+/+ or Ccne1−/− derived bone marrow mononucleated cells (BMCs). 
Cobblestone areas were assessed after 5 wk of culture on stromal feeder layers. (D) CFU assay performed with 20 000 bone marrow mononucleated cells 
(BMCs) isolated from 3 independent mice of the indicated genotypes. Colonies were counted after 10 d of culture. the graph represents the average 
number of colonies scored. the error bar indicates the standard deviation (stdv). (E) FACS analysis of common lymphoid progenitors (CLp: Lin−, ILR7+, Kitlow, 
and Sca1low) and common myeloid progenitors (CMp: Lin−, ILR7−, FcγRII/IIILow, Kit+, and Sca1−) in Ccne1 mice. Bar graphs are the average frequencies ± stdv.
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Normal HSC frequencies in young Ccne1−/− mice
The reduction of colonies scored in the LTC-IC assay in 
Ccne1−/− BMCs could be interpreted either as a numerical or a 
functional deficiency of primitive hematopoietic progenitors and 
HSCs in Ccne1−/− mice. FACS analysis based on surface markers 
revealed similar frequencies of long-term (LT) or short-term (ST) 
HSCs, as well as of multipotent-precursors (MPP) in Ccne1−/− and 
wild-type animals (Fig. 2A; Fig. S3A). Furthermore, assessment 
of dormant HSCs using the CD150 and CD48 marker28,29 did 
not reveal any difference between Ccne1−/− and wild-type litter-
mates (Fig. 2B; Fig. S3B). Next we assessed the cell cycle status 
of HSCs and progenitor populations by FACS by combining the 
analysis of DNA content (Hoechst) with intracellular expression 
of Ki67, a protein expressed in cycling cells, but not in quies-
cent G
0
 cells. Loss of cyclin E1 did not significantly alter the 
cell cycle distribution profiles of LT-HSCs, ST-HSCs, MPPs or 
myeloid progenitors (MPs) (Fig. 2C). Given the lack of numeri-
cal differences in HSCs or progenitor cells isolated from Ccne1−/− 
mice compared with wild-type animals as assessed by FACS, we 
wondered whether loss of cyclin E1 would affect the function 
of these cells. For this purpose, we performed a competitive 
repopulation unit (CRU) assay, which is an in vivo limiting dilu-
tion assay that allows the evaluation of functional HSCs.30 The 
CRU assay revealed similar frequencies of functional HSCs in 
wild-type and Ccne1−/− mice (1:20047 vs 1:23740, P value:0.809, 
details in Table S1). Altogether, we conclude that, in vivo, loss 
of cyclin E1 affected neither the frequency nor the function of 
primitive hematopoietic cells at steady state. Thus, the reduction 
in colonies measured in the LTC-IC assay when culturing WBCs 
derived from Ccne1−/− mice is more likely to reflect an impair-
ment of Ccne1−/− HSCs in undergoing cytokine-mediated pro-
liferation: this condition may be distinct from homeostasis, and 
may rather correspond to a stress response.
Cyclin E1 regulates HSC responses to systemic aplasia
Based on the above data, we hypothesized that, while not 
essential for homeostasis in vivo, cyclin E1 might be limiting in 
situations that require prompt cell cycle re-entry of HSCs, such 
as when the hematopoietic system is facing severe aplasia. To 
address this question, we assessed the recruitment of quiescent 
HSCs into the cell cycle following a single administration of 
the anti-metabolite 5-fluorouracil (5-FU). We first focused our 
analysis at 24 h post-5-FU injection, when HSCs are starting to 
be recruited into the cell cycle in response to treatment.31 At this 
time point, HSCs were still prospectively identifiable, since they 
still presented high levels of c-Kit detectable by FACS (Fig. 3A). 
The frequencies of LT/ST-HSCs or MPPs (Fig. 3A), as well as 
total BMC counts (Fig. 3B), were not significantly different 
between Ccne1+/+ and Ccne1−/− mice, indicating that loss of cyclin 
E1 did not affect the number of hematopoietic cells surviving 
to 5-FU treatment. Since 5-FU selectively eliminates cycling 
cells32,33 this suggests that there is no difference in the number of 
quiescent HSCs in Ccne1+/+ and Ccne1−/− mice prior to treatment. 
This is in line with the observation that at steady-state HSC 
quiescence is not altered by cyclin E1 loss (Fig. 2C; Fig. S3). 
However, 24 h post-5-FU treatment LT-HSCs and ST-HSCs 
isolated from Ccne1−/− mice were significantly more quiescent 
compared with their Ccne1+/+ counterparts (Fig. 3C and D), 
suggesting that cyclin E1 may control the kinetics of cell cycle 
re-entry following myeloablation. Of note, the more differenti-
ated MPPs, showed comparable cell cycle distribution regardless 
the cyclin E1 status (Fig. 3D). Similar results were replicated 
in the inbred C57/Bl6 background: again, no differences were 
recorded in HSC frequencies (Fig. S4A) while a higher fraction 
of quiescent HSCs was measured in Ccne1−/− mice at 24 h post-
5-FU treatment (Fig. S4B).
At longer time points after 5-FU treatment (i.e., 48 h), HSCs 
respond to the myeolablation by starting a self-renewing pro-
liferation and, as a consequence of their cytokine-dependent 
proliferative state,31 display lower level of c-Kit cell surface 
expression. Thus at this stage HSCs can be identified by FACS 
within a population of primitive hematopoietic cells that are 
defined as Lin−, Sca1+, and c-Kitlow (LSKlow, as shown in Fig. 3E). 
Figure 2. FACS analysis of HSCs derived from Ccne1−/− mice. (A) FACS analysis of bone marrow HSCs subpopulations belonging to the Lin−, Sca1+, Kit+ 
(LSK) population by using the Flk2 and CD34 surface markers. Mp, myeloid progenitors (Lin−, Sca− and Kit+); Mpp, multipotential precursors (LSK, Flk2+, 
CD34+); St, short-term HSCs (LSK, Flk2−, CD34+); Lt, long-term HSCs (LSK, Flk2−, CD34−). (B) HSC analysis using the SLAM markers CD48 and CD150 to 
enrich in “dormant” HSCs (LSK, CD34−, CD48− and CD150+). (C) Cell cycle analysis (Ki67/Hoechst) of the different HSC populations and progenitors. Five 
mice for each genotype were used in the experiments described in panels (A–C).
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Remarkably, the kinetics of accumulation of these cells depended 
on cyclin E1, with LSKlow cells accumulating at lower levels in 
Ccne1−/− compared with wild-type mice (Fig. 3E). Thus, the 
lower efficiency of Ccne1−/− HSCs in being recruited into the cell 
cycle after 5-FU treatment correlated with a lower production 
of LSKlow cells, which are responsible for the wave of hemato-
poiesis that follows severe aplasia.31 Accordingly, 4 d after 5-FU 
administration, Ccne1−/− mice showed lower bone marrow cellu-
larity than Ccne1+/+ littermates (Fig. 3F; Fig. S4D), suggesting 
that the impairment in cell cycle entry of Ccne1−/− HSCs results 
in reduced de novo hematopoiesis. To verify this hypothesis, 
we evaluated the kinetics of hematopoiesis by monitoring the 
abundance of white blood cells (WBCs) in peripheral blood for 
up to 24 d following a single 5-fluorouracil treatment. While 
Figure 3. For figure legend, see page 3667.
www.landesbioscience.com Cell Cycle 3667
Ccne1+/+ animals showed the characteristic transient increase 
(rebound) in circulating WBCs, due to HSCs differentiating 
along the myeloid and lymphoid lineages, this effect was blunted 
in Ccne1−/− mice. Thus, cyclin E1-null HSCs have a reduced abil-
ity to enter the cell cycle and give rise to LSKlow HSCs following 
myeloablation, leading to reduced de novo hematopoiesis.
The defective hematopoiesis of Ccne1−/− mice following mye-
loablation would be predicted to lead to an enhanced sensitivity 
to sustained aplasia. To verify this, we subjected mice to weekly 
5-FU treatments and monitored their survival over time. Indeed, 
Ccne1−/− mice showed a significantly reduced overall survival 
compared with wild-type or heterozygous littermates (Fig. 3H; 
Fig. S5). Altogether, our data suggest that the defective cell cycle 
re-entry of quiescent Ccne1−/− HSCs affects their ability to resume 
efficient hematopoiesis following myeloablating treatment, thus 
reducing their ability to effectively face sustained myelotoxic 
stress.
Increased HSC quiescence in aged Ccne1−/− mice
Given the lack of a detectable cell cycle phenotype at steady-
state in the HSCs from young Ccne1−/− animals (8–120-wk-old), 
and considering that the control of cell cycle dynamics in HSCs 
is age-dependent,11,34 we studied a cohort of 23-mo-old mice. 
FACS analysis showed equal frequencies of LT/ST-HSCs, MPPs 
or MPs in aged Ccne1−/− and wild-type animals (Fig. 4A). Yet, we 
measured a statistically significant increase in the proportion of 
quiescent LT/ST-HSCs, with an average of 75% of quiescent LT/
ST-HSCs in Ccne1−/− compared with 60% in Ccne1+/+ animals 
(Fig. 4B and C). Of note the cell cycle distribution of MPPs 
and myeloid progenitors (MPs) was not affected by cyclin E1 loss 
(Fig. 4B and C), thus indicating a specific function of cyclin E1 
in regulating the cell cycle in the HSC compartment.
Loss of cyclin E1 provides competitive advantage to HSCs
We finally assessed HSC function in competitive bone marrow 
transplants. Ccne1−/− or wild-type “test” BMCs (expressing the 
Ly5.2 epitope) were transplanted together with equal amounts 
of competitor congenic BMCs (expressing the Ly5.1 epitope). 
In line with the results of the CRU assay, mutant and wild-type 
cells were equally efficient in producing long-term hematopoiesis 
in primary recipients. After long-term engraftment, BMCs were 
transplanted from the primary into secondary recipients, and the 
same procedure was repeated serially into tertiary and quaternary 
recipients. At each passage, we evaluated long-term hematopoi-
esis in peripheral blood by monitoring the relative proportions 
of Ly5.1+ and Ly5.2+ WBCs. Loss of cyclin E1 endowed HSCs 
with a competitive advantage upon serial transplantation, since 
ternary and quaternary recipient of cyclin E1-deficient BMCs 
displayed stronger long-term hematopoiesis compared with mice 
that had received wild-type BMCs (Fig. 5A). Similar results 
were obtained when using wild-type or cyclin E1-null mice of 
a C57/129 mixed background that were also transgenic for GFP 
(Fig. 5B). Altogether, our data suggest that loss of cyclin E1 lim-
its the exhaustion of the HSC compartment when exposed to 
the highly proliferative response that follows bone marrow trans-
plantation, resulting in increased resilience of HSCs upon serial 
transplantation.
Discussion
We have used mice lacking cyclin E1 to study the role of 
this protein in HSCs biology. Our data show that cyclin E1 
regulates the kinetics of cell cycle entry of quiescent stem cells 
following severe pancytopenia caused by myeloablating treat-
ments such as 5-FU injection, thereby affecting their efficiency 
in generating differentiated progenitors. Indeed, the slower cell 
cycle entry measured in Ccne1−/− HSCs following 5-FU treat-
ment correlated with a lower accumulation of LSKlow cells, a 
population of cells comprising self-renewing HSCs and highly 
proliferating early progenitors which are generated following 
aplasia.31 A reduction of the LSKlow cells is likely to impact on 
downstream hematopoiesis, and, in fact, we consistently mea-
sured a lower rebound of circulating WBCs in Ccne1−/− mice, 
thus suggesting that cell cycle entry and proliferation rates of 
primitive progenitors (i.e., LSKlow cells) affect the efficiency of 
hematopoiesis.
It is important to note that Ccne1−/− HSCs are not inherently 
sensitized to 5-FU treatment since: (1) in homeostatic conditions 
they are as quiescent as their wild-type counterpart (Fig. 2C); 
and (2) upon myeloablation, the fraction of surviving HSCs is 
comparable in either genetic background (Fig. 3A). Moreover, 
the relative increase in quiescence observed in Ccne1−/− HSCs at 
24 h post 5-FU (Fig. 3B; Fig. S4B) is not expected to provide 
any protective effect upon repeated 5-FU administration: indeed, 
despite the lower kinetics of cell cycle exit, by the time the sub-
sequent treatment was administered all the Ccne1−/− HSCs had 
entered the cell cycle and had converted into LSKlow (Fig. 3E). 
The impairment of stress-induced hematopoiesis observed in 
Figure 3 (See opposite page). Cyclin e1 regulates HSCs following myeloablation. (A) prospective identification of HSCs and progenitors in Ccne1 mice 
by FACS analysis of bone marrow mononucleated cells (BMCs) isolated from Ccne1 mice 24 h following 5-FU administration. on the left, FACS profiles of 
Lin− cells stained with c-Kit and Sca1 are shown. the red box outlines the gating for the LSK cells used to define Lt-HSC, St-HSC and Mpp (as described to 
in Fig. 2). Frequencies of the different LSK cells are represented in the bar graph on the right. the bar graph represents the average values relative to the 
different LSK population of cells; error bars are the standard deviation, n = 7. (B) Assessment of BMCs, at 1 d post-5-FU treatment (n = 7). Values are the aver-
age of the total count of cells isolated from 2 tibias and 2 femurs/mouse. (C) Cell cycle distribution by FACS analysis of the different HSC/progenitor popu-
lations of cells as shown in (A), stained for the proliferation marker Ki67 and the DNA dye Hoechst. (D) Analysis of quiescence (i.e., percentage of cells in G0) 
based on the FACS profiles shown in (C). Bar graph is the average percentage of quiescent cells ± stdv, n = 7. (E) Analysis of the kinetics of accumulation of 
the LSKlow following a single injection of 5-FU. FACS profiles of Lin− cells stained with c-Kit and Sca1 are shown on the left; the red box highlights the LSKlow 
gate used. Quantitation of LSKlow cells is shown on the right as average cells ± stdv, n = 3. (F) Assessment of BMCs 4 d post 5-FU treatment (n = 4). Values 
are the average of the total count of cells isolated from 2 tibias and 2 femurs/mouse. (G) A cohort of Ccne1+/+ or Ccne1−/− mice (n = 6) was injected with 5-FU 
(200 mg/Kg) at day 0. peripheral white blood cells (WBCs) were counted at defined days; data were normalized to values measured before 5-FU treatment 
and plotted as average ± stdv. the count of white blood cells at day 14 is also reported in the inset. (H) Kaplan–Mayer survival curves of different cohorts of 
mice of the indicated genotypes subjected to 5-FU injections (150 mg/Kg) every 7 d, as indicated by the arrows. Ccne1−/− = 8, Ccne1+/+ = 5, and Ccne1+/− = 4.
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Ccne1−/− mice also accounts for their sensitivity to a regimen of 
continuous 5-FU administration: since this treatment causes the 
progressive erosion of HSCs, Ccne1−/− mice, which show defective 
stress-induced hematopoiesis, are likely to fall below the survival 
threshold sooner than wild-type mice.
Contrary to what observed in young animals, where cyclin E1 
is dispensable for controlling HSC homeostasis, loss of cyclin E1 
resulted in a higher proportion of quiescent HSCs in aged mice 
compared with aged matched littermates. This effect of cyclin 
E1 most probably reflects intrinsic changes in the way the cell 
cycle is controlled in aged HSCs, as exemplified by the accu-
mulation of the CDK inhibitors (CKI) p21 and p18.34 Likewise, 
p16 expression has been reported to increase with HSCs aging,11 
although whether this may represent a general feature of aging 
HSCs is still debated.35
Such alterations bear direct consequences on cell cycle 
dynamics, since p21 directly inhibits cyclin E/CDK2 activity, 
while inhibition of cyclin D/CDK4,6 complexes by p18 would 
be expected to render cell cycle progression critically dependent 
on cyclin E activity, as demonstrated by studies on CDK4,6 dou-
ble KO and cyclin D1–3 triple KO cells.13,14 In this setting, the 
reported downregulation of cyclin E2 expression in aged HSCs34 
may explain why cyclin E1 becomes limiting.
We also notice that our aged mice, regardless of their Ccne1 
status, showed increased HSC quiescence compared with young 
animals of the same genotype: while this observation is coherent 
with studies showing a progressive decrease in the proliferative 
and self-renewal potential of HSCs during aging,11,34,36-38 it is in 
contrast with early work reporting increased proliferation of aged 
HSCs.39 Methodological differences may account in part for this 
discrepancy: here, we used Ki67 as a marker for defining quies-
cent cells in HSCs, as opposed to BrDU incorporation, which 
was used in earlier studies and is now known to intrinsically alter 
the cell cycle distribution in HSCs.29 This notwithstanding, our 
analysis indicates that loss of cyclin E1 affects quiescence of LT/
ST HSCs during aging.
Figure 4. Cyclin e1 regulates quiescence of aged HSCs. (A) prospective identification of HSCs and progenitors in cyclin e1 mice of C57/Bl6 background 
by FACS analysis. Bone marrow mononucleated cells (BMCs) were isolated from Ccne1+/+ (n = 10) or Ccne1−/− (n = 6) mice aged for 23 mo. Bar graphs report 
the average value, error bars are the standard deviation. HSCs, LSK (Lin−, Sca1+, Kit+); Mpp, multipotential precursors, (LSK, Flk2+); Lt/St, short-term and 
long-term HSCs (LSK, Flk2−). (B) Cell cycle analysis of HSCs and myeloid progenitors (Mp), cell cycle distribution was determined by FACS based on the 
Hoechst/Ki67 staining of the different cell populations. (C) FACS profiles of the analysis shown in (B)
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In previous studies, neither Ccne1−/− nor Ccne2−/− mice showed 
detectable phenotypes.23,24 The lack of redundancy that we report 
here for cyclin E1 in HSCs may in principle be due to: (1) a pecu-
liar function of cyclin E1 not shared by cyclin E2, or (2) dif-
ferential expression of the Ccne1 and Ccne2 genes in HSCs, such 
that cyclin E2 is not available to compensate for the absence of 
cyclin E1. In favor of the latter hypothesis, the Ccne1 but not 
the Ccne2 mRNA is upregulated in HSCs following cyclophos-
phamide and G-CSF administration,40 which similarly to 5-FU 
activates quiescent HSCs and induces cell cycle entry.41
At a mechanistic level, we speculate that the defective cell 
cycle entry of Ccne1−/− HSCs may be related to the requirement of 
cyclins E1 and E2 for the loading of MCM complexes onto rep-
lication origins during cell cycle entry but not in the continuous 
cell cycle, as demonstrated in MEFs,42 a role for which cyclin E1 
alone may be rate-limiting in HSCs.
Although endowed with self-renewal capacity and generally 
considered long-lasting cells, HSCs are not immortal and are 
subjected to aging and exhaustion following serial transplanta-
tion.43-45 HSCs will self-renew at each transplant46 to recreate the 
HSC pool and at the same time will differentiate to support sys-
temic hematopoiesis.47 These reiterated cycles of self-renewal and 
hematopoiesis have an impact on the lifespan of HSCs, and upon 
serial transplantation, HSCs will reach a point in time at which 
Figure 5. Serial bone marrow transplants of Ccne1+/+ or Ccne1−/− BMCs (A) Ly5.2 BMCs from Ccne1+/+ or Ccne1−/− mice were transplanted in a 1:1 ratio with 
competitor cells derived from Ly5.1 C57/Bl6 mice into Ly5.2/Ly5.1 recipient mice. After long-term reconstitution (5 months), peripheral blood chimerism 
was assessed by FACS. BMCs derived from primary recipients were then transplanted into secondary recipients. the process was repeated until the 4th 
bone marrow transplant. Data were plotted as averages of the Ly5.2+ peripheral blood nucleated cells normalized to the total cells transplanted (Ly5.1+ 
+ Ly5.2+ cells). Numbers within graph bars indicate the number of recipients used in each transplant. (B) GFp+ BMCs from Ccne1+/+ or Ccne1−/− mice were 
transplanted in a 1:1 ratio with competitor BMCs from C57/Bl6 mice into C57/129 F1 hybrids. the experiment was performed as in (A). After long-term 
reconstitution (5 mo) GFp+ cells were determined in peripheral blood by FACS analysis and reported as average percentage ± standard deviation. 
Numbers within graph bars indicate the number of recipients used in each transplant.
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they will be unable to support hematopoiesis. In this context, 
a defective exit from quiescence of HSCs, while still permissive 
for efficient hematopoiesis, would be expected to limit the self-
renewing proliferation, thereby delaying their exhaustion upon 
serial transplantation. Thus, paradoxically, a moderate ineffi-
ciency in cell cycle entry will exert a protective effect and will 
endow cells with a competitive advantage, as we indeed observed 
with Ccne1−/− relative to wild-type HSCs. Alternatively, a reduc-
tion of cyclin E levels may limit the hyper-mitogenic drive that 
follows HSCs transplantation, thus preventing replicative stress 
responses and accelerated aging due to cellular senescence.48,49 It 
is noteworthy that the mTOR pathway plays a relevant role in 
controlling such activities, since mTOR inhibition prevents repli-
cative senescence50 and reverts some of the phenotypes associated 
with HSCs aging.51 In a mirror image to our findings on cyclin 
E1, a similar mechanism has been proposed to explain the pro-
tective roles of the CDK inhibitors p16 and p21 in limiting HSC 
depletion during serial transplantation.5,11
Logically, while protective upon serial bone marrow transfer, 
the reduced cell cycle entry of Ccne1−/− HSCs constitutes a dis-
advantage for hematopoiesis following acute myeloablation. By 
analogy, such a dual effect may apply to chemical inhibition of 
CDK activities in cancer cells, where inhibition of cell cycle entry 
may turn out to be protective to cancer stem cells.19
Materials and Methods
Mice
Ccne1- and Ccne2-knockout (KO) mice of C57/129 mixed 
background24 were backcrossed into a C57BL/6J background 
for nine generations. To perform some of the bone marrow 
transplant experiments described, Ccne1-null mice of C57/129 
mixed background, were crossed with GFP transgenic mice 
(C57BL/6TgN[ACTbEGFP]). Unless otherwise stated, all 
experiments were performed on 8–12-week-old mice of C57/129 
background. Mouse colonies were maintained in a certified ani-
mal facility in accordance with national guidelines.
FACS analysis
The following antibodies were used: anti-mouse CD117 
(clone 2B8; PE, APC, or PE-Cy5.5 conjugated; eBioscience), 
anti-mouse Ly-6A/E (clone D7; FITC, PE, PE-Cy5.5, or Biotin 
conjugated; eBioscience), anti-mouse CD34 (clone RAM34; 
Biotin, FITC, or APC conjugated; eBioscience), anti-mouse 
CD135 (clone A2F10, PE conjugated; eBioscience), anti-mouse 
CD127 (Interleukin-7 Receptor, A7R34, PE conjugated; eBiosci-
ence), anti-mouse CD48 (clone HM48-1, PE or Biotin conju-
gated, eBioscience), anti-mouse CD150 (clone TC15–12F12.2, 
PerCP/Cy5.5 conjugated, Biolegend) anti-mouse CD16/32 
(blocks Fc binding, clone 93, PE conjugated; eBioscience), anti-
mouse CD45.1 (clone A20, FITC conjugated; eBioscience), 
anti-mouse CD45.2 (clone104, PE conjugated; eBioscience). For 
lineage-specific staining the following lineage specific antibodies 
were used: anti-mouse Cd11b, anti-mouse GR1, anti-mouse Ter-
119, anti-mouse CD3ε, anti-mouse CD4, anti-mouse CD8 and 
anti-mouse B220, (PE-CY7 conjugated, eBioscience). Cell cycle 
analysis was performed by FACS as previously described.29
CFU, CAFC, and LTC-IC assay
Stromal layers were prepared from the wild-type bone mar-
row cells, cultured in IMDM supplemented with 12.5% horse 
serum, 12.5% FBS, penicillin, streptomycin, 1 μM hydrocorti-
sone, and 50 μM 2-mercaptoethanol at 37 °C. After 3 wk, when 
stromal layers are typically confluent, cells were irradiated (15 
Gy) and sub-cultured in 6-well plates. Feeder layers were seeded 
with bone marrow cells (2.5 × 105 per well) and cultured long 
term. For LTC-IC (long-term culture initiating cell) assay,52 bone 
marrow mononucleated cells (BMCs) cultured for 5 wk on stro-
mal layers were seeded in methylcellulose (Methocult SF M3226, 
Stem Cell Technology) supplemented with 15% FCS, 2 ng ml−1 
IL3, 2 ng ml−1 IL6, 50 ng ml−1 SCF, 60 ng ml−1 G-CSF, and 20 ng 
ml−1 GM-CSF (Peprotech). Colonies were scored after 10 d. The 
CAFC (cobblestone area forming cell) assay was performed after 
5 wk of culture on feeder layers as previously described.25 For 
CFU (colony-forming unit) assay, 20 000 bone marrow nucleated 
cells were seeded in methycellulose media supplemented with dif-
ferent sets of differentiating cytokines. Myeloid differentiation 
was assessed as described above. For lymphoid differentiation, 
methylcellulose cultures were supplemented with 20 ng/mL Flt3 
and 10 ng/mL IL-7 (Peprotech), while erythroid differentiation 
medium was assessed seeding cells in MethoCult® M3334 sup-
plemented with 2 ng ml−1 IL3 and 50 ng ml−1 SCF. Colonies were 
typically scored after 10–12 d of culture.
Bone marrow transplants experiments
One million test cells (Ly5.2+) (3 mice for each genotype) 
and 1 × 106 cells derived from C57BL/6-CD45.1 congenic mice 
(Ly5.1+) were pooled and injected into the tail vein of lethally irra-
diated C57BL/6-CD45.1/CD45.2 F1-hybrids. Recipients’ PB was 
analyzed for donor contribution by flow cytometric analysis. After 
long-term reconstitution (5–6 mo), 2 × 106 bone marrow cells 
derived from primary recipients were injected into lethally irradi-
ated secondary recipients. This process was reiterated until reaching 
the fourth round of transplants. To minimize clonal dominance, 
each serial transplant was repeated twice using as donors 2 differ-
ent pools of BMCs derived from 3 independent donors.
A similar protocol was used for cyclin E1 mice of mixed back-
ground where 106 Ccne1+/+ or Ccne1−/− GFP-positive cells were 
transplanted in competition with 106 bone marrow cells derived 
from C57BL/6 mice. Chimerism was assessed by FACS analysis 
of GFP-positive cells in peripheral blood. For competitive repop-
ulation unit assay (CRU assay) recipients, C57BL/6 Ly5.1 mice 
lethally irradiated (9.5 Gy) the day before transplantation were 
injected with 15 × 103, 5 × 104, or 2 × 105 Ly5.2+ test bone marrow 
cells, together with 2 × 105 congenic BMCs (Ly5.1+). Peripheral 
blood chimerism was determined 4–6 mo post-transplant by 
FACS analysis to assess relative percentages of Ly5.2- and Ly5.1-
positive cells in the peripheral blood. A recipient with less than 
2% of Ly5.2+ leukocytes was defined as negative. CRU numbers 
were determined by Poisson statistical analysis (L-Calc software, 
StemCell Technologies).
5-FU treatments
5-FU (TEVA, 5 g/mL) was administered intraperitoneally at 
a dose of either 200 mg/Kg, for single injections, or 150 mg/Kg, 
for weekly treatments.
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Statistical analysis
In all figures, data are presented as the mean ± standard 
deviation. Statistical significance was calculated using a 2-tailed 
Student t test. Results from survival experiments were analyzed 
with a log-rank non-parametric test and expressed as Kaplan–
Meier survival curves.
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